An intracameral injection delivers medication directly into the anterior chamber of the eye, the fluid-filled space between the cornea and the iris. This route bypasses the barriers that limit how much drug actually reaches the inside of the eye when drops are applied to the surface. Eye drops lose the vast majority of their payload to blinking, tear drainage, and the corneal barrier, with studies showing that less than 4% of a topically applied drug typically reaches the aqueous humor.1Frontiers in Drug Delivery. Topical ophthalmic administration: Can a drug instilled onto the ocular surface exert an effect at the back of the eye? Intracameral injection sidesteps all of that, and its growing list of clinical uses reflects just how much of a difference that directness makes.
How the Injection Is Performed
The procedure itself is quick and typically happens in an operating room or, in some cases, at a slit lamp. The surgeon enters the eye through the clear cornea using a fine-gauge needle, usually 26- or 27-gauge. A temporal approach is preferred when the patient is lying down, since it gives the surgeon a natural angle of entry. The needle is angled bevel-up, tracking through the cornea far enough to create a self-sealing tunnel, and kept well away from the central visual axis and the natural lens. Once inside the anterior chamber, the medication is injected in a controlled, slow push. The needle is then withdrawn gradually, and a cotton-tipped applicator is pressed gently against the wound to prevent fluid from leaking out.2Journal of Glaucoma. Evolving Guidelines for Intracameral Injection
For antibiotic prophylaxis during cataract surgery, a common protocol involves drawing up a small volume of diluted antibiotic into a tuberculin syringe, then injecting about 0.1 mL into the anterior chamber through the existing paracentesis wound at the end of the case.3PubMed Central. Preparation of intracameral antibiotics for injection The whole injection step takes seconds. For sustained-release implants like those used in glaucoma, the procedure involves a slightly different inserter device, but the corneal entry pathway is essentially the same.
Why Not Just Use Eye Drops
The bioavailability gap between drops and intracameral delivery is enormous. When researchers have used intracameral injection as a reference standard to measure how much drug actually penetrates the eye from a topical dose, the numbers are striking. In one study comparing topical flurbiprofen to an intracameral dose (which is considered fully bioavailable to the interior of the eye), the topical formulation delivered only about 7 to 10% of the drug to the aqueous humor.4PubMed. Ocular and systemic bioavailability of ophthalmic flurbiprofen A similar pharmacokinetic study of brinzolamide, a glaucoma drug, found that topical application of a 1% suspension achieved an absolute bioavailability of just 0.10% compared to the intracameral dose.5Journal of Pharmaceutical Sciences. Comprehensive Ocular and Systemic Pharmacokinetics of Brinzolamide in Rabbits After Intracameral, Topical, and Intravenous Administration That means topical drops delivered roughly one-thousandth of the drug to where it needed to be.
This does not mean eye drops are useless. They work well enough for many conditions, and they avoid the need for a needle in the eye. But when you need a high, reliable drug concentration inside the anterior chamber right now, or when a patient cannot be trusted to use drops consistently for months, the intracameral route has clear advantages.
Preventing Infection After Cataract Surgery
Endophthalmitis, a devastating infection inside the eye, is the nightmare scenario after cataract surgery. It is rare even without prophylaxis, but the consequences when it does occur can include permanent vision loss. Injecting an antibiotic directly into the anterior chamber at the end of cataract surgery has become one of the most effective preventive strategies available. A meta-analysis of studies comparing intracameral cefuroxime and moxifloxacin to controls found that both antibiotics reduced endophthalmitis rates with minimal toxicity at standard doses.6PubMed Central. Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis
Real-world data from a large Indian study put numbers to the effect. After introducing intracameral antibiotics, the rate of acute endophthalmitis after cataract surgery dropped by about 72%, falling from 0.126% to 0.035%. Both cefuroxime and moxifloxacin achieved statistically significant reductions individually, and neither was clearly superior to the other.7PubMed Central. Endophthalmitis prophylaxis study. Report 1: Intracameral cefuroxime and moxifloxacin prophylaxis for the prevention of postcataract endophthalmitis in rural India By the time surveys of European cataract surgeons were conducted, roughly three quarters reported routinely using intracameral antibiotics, with the vast majority choosing cefuroxime.
The economics reinforce the clinical picture. A cost-effectiveness analysis calculated that intracameral cefuroxime costs about $1,400 per case of endophthalmitis prevented. Topical fluoroquinolone drops would need to be 8 to 19 times more effective than intracameral cefuroxime just to match its cost-effectiveness, depending on which drop was used.8Ophthalmology. Cost-Effectiveness Analysis of Intracameral Cefuroxime Use for Prophylaxis of Endophthalmitis after Cataract Surgery A systematic review confirmed that intracameral cefuroxime showed the best cost-effectiveness ratio among available prophylaxis regimens.9PubMed Central. Intracameral cefuroxime and moxifloxacin used as endophthalmitis prophylaxis after cataract surgery: systematic review of effectiveness and cost-effectiveness
Pupil Dilation During Cataract Surgery
Cataract surgery requires a wide, stable pupil so the surgeon can see and access the lens. Traditionally, this is achieved with a series of dilating drops given over 30 to 60 minutes before the procedure. An intracameral combination of mydriatics (pupil-dilating agents) and anesthetic offers a dramatically faster alternative. In one study, 95% of pupil dilation occurred within a mean of about 29 seconds after the intracameral combination was delivered.10Journal of Cataract & Refractive Surgery. Pupil dilation dynamics with an intracameral fixed combination of mydriatics and anesthetic during cataract surgery
Speed is not the only benefit. The intracameral approach also held the pupil more stable throughout surgery. In the group receiving the intracameral combination, the pupil shrank by less than a millimeter between the start and the end of surgery in nearly 90% of eyes. Only about 27% of eyes in the topical-drop group managed the same stability. Patients receiving the intracameral combination also spent significantly less time in the preoperative and surgical areas combined, averaging roughly 23 minutes compared to about 49 minutes for the topical-drop group.11PubMed Central. Evaluation of the efficacy and safety of a standardised intracameral combination of mydriatics and anaesthetics for cataract surgery For busy surgical centers running many cases per day, that time difference is substantial.
Sustained-Release Implants for Glaucoma
Glaucoma is a chronic disease that typically demands daily eye drops for years or decades, and adherence to those drops is notoriously poor. Many patients forget doses, struggle with the physical act of instilling drops, or experience surface irritation that makes them want to stop.12PubMed Central. Sustained-release drug delivery systems for the treatment of glaucoma The idea behind intracameral sustained-release implants is simple: put the drug inside the eye once and let it release slowly over months, removing the patient from the compliance equation entirely.
The first product to reach the market was a biodegradable bimatoprost implant (Durysta), which is injected into the anterior chamber and gradually releases bimatoprost, a prostaglandin analog. It provides pressure-lowering effects comparable to daily prostaglandin eye drops, with the advantage that the patient does not need to do anything after the procedure.13PubMed Central. Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation A meta-analysis comparing intracameral prostaglandin implants found that bimatoprost implants achieved mean pressure reductions of about 6 to 7 mmHg at 12 months. Travoprost-based implants under development showed somewhat variable results depending on the study, though they were broadly comparable to the lower-dose bimatoprost implant at shorter follow-up periods.14PubMed. Sustained-Release Intracameral Prostaglandin Analog Implants for Glaucoma: Comparative Review and Meta-Analysis of Bimatoprost and Travoprost Delivery Systems
An 18-month real-world study tracked patients who received the bimatoprost implant in routine clinical practice. Pressure reductions ranged from 1 to 2 mmHg on average across follow-up visits, and an estimated 78% of eyes required no additional medication for pressure management throughout the study period.15PubMed Central. Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice Patients also used fewer daily eye drops after the implant. On average, they reduced their drop burden by about half a medication at the 12-month mark compared to baseline.16PubMed. Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant
Corneal Endothelial Cell Concerns with Implants
The corneal endothelium, a single layer of cells on the inner surface of the cornea, does not regenerate in humans. Any procedure that involves placing something inside the anterior chamber risks damaging these cells, and intracameral implants sit in close proximity to them for months. This is one of the more carefully watched safety endpoints for sustained-release glaucoma devices.
In the ARTEMIS 2 phase 3 trial, eyes receiving the 10 µg bimatoprost implant lost about 5% of their corneal endothelial cells by 20 months, compared to roughly 1% in eyes receiving topical timolol drops. The higher 15 µg dose caused more corneal complications, including endothelial cell loss and corneal edema, particularly after repeated administrations.17PubMed Central. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2) A separate phase 3 trial comparing the implant to selective laser trabeculoplasty found a mean endothelial cell loss of about 6% in implant-treated eyes at 24 months, versus about 3% in laser-treated eyes, with the fixed readministration group losing closer to 8%.18American Journal of Ophthalmology. Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty
For most patients, a few percent of cell loss over a couple of years is manageable since there is a large functional reserve. But repeated implantation over many years could accumulate losses that matter, and clinicians are understandably cautious about long-term use in younger patients or those with pre-existing endothelial compromise.
Clearing Fibrin Clots and Treating Abnormal Blood Vessels
Intracameral injection is not limited to prophylaxis or chronic disease management. It is also used as a rescue therapy when things go wrong inside the eye. One classic example is injecting tissue plasminogen activator (tPA), a clot-dissolving enzyme, to clear fibrin or blood clots that form in the anterior chamber after surgery or in eyes with glaucoma drainage devices.
In a series of 36 eyes with valved glaucoma implants that developed tube occlusion from fibrin or blood, intracameral tPA successfully cleared or prevented the blockage in about 89% of cases. The average pressure drop 24 hours after the injection in eyes with fully occluded tubes was dramatic, falling by roughly 21 mmHg. Complications, including severe bleeding, low pressure, and chamber flattening, occurred after about 11% of injections.19JAMA Ophthalmology. Intracameral Tissue Plasminogen Activator Use in a Large Series of Eyes With Valved Glaucoma Drainage Implants A separate study using a low-dose tPA protocol for fibrinous membranes found that 84% dissolved within 2 to 12 hours, with complete resolution in all cases by 3 days and no hemorrhagic complications.20Journal of Cataract & Refractive Surgery. Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation
Abnormal new blood vessels growing on the iris, a condition called rubeosis iridis often driven by diabetes or retinal vein occlusion, can also be targeted with intracameral anti-VEGF drugs like bevacizumab. Injecting bevacizumab directly into the anterior chamber in a small series of eyes with iris rubeosis showed decreased leakage from the abnormal vessels as early as one day after injection, with no relapse seen within a four-week follow-up.21American Journal of Ophthalmology. Intracameral Bevacizumab for Iris Rubeosis In neovascular glaucoma, the pressure-lowering effect of intracameral bevacizumab appeared within a week but was limited to about three weeks on average, buying time for additional procedures like laser or surgery that offer more durable control.22Ophthalmologica. Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma
Controlling Inflammation After Surgery
Some surgeons inject a steroid directly into the anterior chamber at the end of cataract surgery to get a head start on controlling postoperative inflammation. A study comparing intracameral dexamethasone to intracameral triamcinolone found both equally effective at suppressing inflammation in the first day after surgery. However, the triamcinolone group had higher eye pressure on postoperative day one, likely due to the particulate structure of the drug. The highest recorded pressure in that group was 24 mmHg, which resolved within days, but the authors noted this could matter in patients with glaucoma, making dexamethasone the preferable choice for those individuals.23PubMed Central. Comparison of intracameral dexamethasone and intracameral triamcinolone acetonide injection at the end of phacoemulsification surgery
Fungal Infections
Fungal keratitis, a corneal infection caused by organisms like Fusarium or Aspergillus, can be extraordinarily difficult to treat. Standard topical antifungal drops penetrate poorly, and some infections progress despite aggressive topical therapy. Intracameral voriconazole injection has emerged as a treatment option for cases that resist conventional therapy. In a series of 10 eyes with fungal endophthalmitis spreading from corneal infections, intracameral voriconazole injections showed promising results.24PubMed. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis Another study found intracameral voriconazole had similar therapeutic effect to intracameral amphotericin B, but with a potentially better safety profile for the delicate intraocular tissues.25Journal of the Korean Ophthalmological Society. Clinical Effects of Intracameral Voriconazole Injection in Patients with Fungal Keratitis Refractory to Conventional Treatment
In particularly stubborn cases, combining intracameral with intrastromal injection, where the drug is placed directly into the corneal tissue, has shown benefit. A case report of recalcitrant Acremonium keratitis described marked improvement beginning three days after this combined approach, with the result sustained through six months of follow-up.26PubMed Central. Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis
Risks and Complications
Intracameral injection is generally safe when done properly, but the margin for error is narrow because the anterior chamber is a small, enclosed space. Dosing accuracy matters enormously. Laboratory work has shown that cefuroxime concentrations above a certain threshold cause significant damage to corneal endothelial cells, and the safety window between a therapeutic dose and a toxic one is not wide.27PubMed Central. Toxic anterior segment syndrome after uncomplicated cataract surgery possibly associated with intracamaral use of cefuroxime A case of severe anterior segment toxicity was reported after undiluted, high-volume moxifloxacin was injected intracamerally, a dosing error that caused a condition known as toxic anterior segment syndrome, or TASS.28PubMed Central. Toxic Anterior Segment Syndrome with Intracameral Moxifloxacin: Case Report and Review of the Literature
TASS is the complication that gets the most attention because it can mimic an infection while actually being a sterile inflammatory reaction, often caused by incorrect drug concentration, contaminated solutions, or residual detergent on instruments. It typically presents within 24 hours of surgery with diffuse corneal edema and anterior chamber inflammation.
Pressure spikes are another risk. In one case, a viscoelastic substance (Healon 5) injected intracamerally to support the anterior chamber after a glaucoma procedure caused pressure to spike to 70 mmHg within 12 hours. Emergency washout of the viscoelastic resolved the problem rapidly, with the pressure dropping to 14 mmHg and vision recovering to near-normal.29Journal of Glaucoma. Severe Intraocular Pressure Elevation After Intracameral Healon 5 Viscoelastic Support for Postoperative Hypotony After XEN Gel Stent Insertion Preservatives commonly found in ophthalmic solutions can also cause damage if injected intracamerally. Benzalkonium chloride, a preservative used in many eye drops, causes dose-dependent endothelial toxicity when placed directly inside the anterior chamber, which is why preservative-free formulations are critical for intracameral use.30PubMed Central. A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits
Emerging Frontiers in Cell Therapy
One of the more experimental applications of the intracameral route involves injecting cultured human corneal endothelial cells to treat bullous keratopathy, a painful condition caused by endothelial failure. Because these cells do not regenerate on their own, the standard treatment has historically been a corneal transplant. A recently described technique uses a long, tangential corneal tunnel created with a 26-gauge needle to inject cultured cells into the anterior chamber, where they can settle on the inner corneal surface and potentially restore function.31PubMed. A Modified Long Corneal Tunnel Technique for Intracameral Injection in Cultured Human Corneal Endothelial Cell Therapy (Vyznova): A Preliminary Technical Report If this approach matures, it could transform the treatment of corneal endothelial disease by replacing surgery with a brief injection, dramatically expanding access for patients in regions where donor corneas are scarce.